SEC Form 4 · accession 0001140361-15-012558

SANGAMO THERAPEUTICS, INC · SGMO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President & CEO · Director

Period of report

Mar 16, 2015

Accepted (ET)

Mar 18, 2015 · 8:02 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001001233

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Mar 16, 2015	M	25,000	$6.82	A	260,000	D
Common Stock^F3,F1	Mar 16, 2015	S	25,000	$17.2922	D	235,000	D
Common Stock^F4	Mar 17, 2015	G	3,500	$0.00	D	1,185,521	I	By Trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (Right to Buy)^F5	$6.82	Mar 16, 2015	M	25,000	D	—	Dec 12, 2016	Common Stock	25,000	125,000	D

F1Includes 60,000, 50,000 shares and 125,000 subject to RSUs granted on December 6, 2012, December 12, 2013 and December 11, 2014, respectively, that will be issued as such units vest in accordance with their terms.
F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 20, 2014.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.04 to $17.48, inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F4These shares are held in the Edward O. Lanphier II and Cameron M. Lanphier Trust U/T/A August 30, 2002, Edward O. Lanphier II and Cameron M. Lanphier, Trustees.
F5All shares underlying these options are vested and exercisable immediately.